Kiora Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)	Preferred Stock Series C Preferred Stock	Preferred Stock Series D Preferred Stock	Preferred Stock	Common Stock Series C Preferred Stock	Common Stock Series D Preferred Stock	Common Stock Private Placement	Common Stock Registered direct offering	Common Stock	Additional Paid-In Capital Series C Preferred Stock	Additional Paid-In Capital Series D Preferred Stock	Additional Paid-In Capital Private Placement	Additional Paid-In Capital Registered direct offering	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Private Placement	Registered direct offering	Total
Balance at Dec. 31, 2019			$ 41					$ 40,778					$ 106,689,065	$ 139,465	$ (100,246,894)			$ 6,622,455
Balance (in shares) at Dec. 31, 2019			4,092					4,077,755
Stock-Based Compensation													723,856					723,856
Issuance of Common Stock in Offerings, Net of Offering Costs								$ 5,000					4,496,313					4,501,313
Issuance of Common Stock in Offerings, Net of Offering Costs (in shares)								500,000
Issuance of Common Stock from Warrants, Net								$ 454					217,546					218,000
Issuance of Common Stock from Warrants, Net (in shares)								45,417
Shares Issued to Panoptes Stockholders at Acquisition								$ 8,842					3,157,282					3,166,124
Shares Issued to Panoptes Stockholders at Acquisition (in shares)			46					884,222
Dissolution of Foreign Entity														(113,717)				(113,717)
Issuance of Common Stock from Restricted Stock Award Grants								$ 490					(490)
Issuance of Common Stock from Restricted Stock Award Grants (in shares)								49,000
Foreign Currency Translation Adjustment														(26,550)				(26,550)
Net Loss															(8,091,940)			(8,091,940)
Balance at Dec. 31, 2020			$ 41					$ 55,564					115,283,572	(802)	(108,338,834)			6,999,541
Balance (in shares) at Dec. 31, 2020			4,138					5,556,394
Stock-Based Compensation													842,475					842,475
Conversion of Preferred Stock into Common Stock	$ (41)			$ 8,525	$ 109				$ (8,484)	$ (109)
Conversion of Preferred Stock into Common Stock (in shares)	(4,092)	(39)		852,500	10,911
Issuance of Common Stock in Offerings, Net of Offering Costs						$ 15,311	$ 46,689				$ 7,973,550	$ 9,709,659				$ 7,988,861	$ 9,756,348
Issuance of Common Stock in Offerings, Net of Offering Costs (in shares)						1,531,101	4,668,844
Shares issued to Bayon Shareholders at Acquisition								$ 338					67,598					67,936
Shares issued to Bayon Shareholders at Acquisition (in shares)								33,798
Issuance of Common Stock from Warrants, Net								$ 104					49,897					50,001
Issuance of Common Stock from Warrants, Net (in shares)								10,417
Dissolution of Foreign Entity																		0
Conversion of Stock into Common Stock(in shares)	4,092	39		(852,500)	(10,911)
Foreign Currency Translation Adjustment														(85,629)				(85,629)
Net Loss															(16,394,919)			(16,394,919)
Balance at Dec. 31, 2021								$ 126,640					$ 133,918,158	$ (86,431)	$ (124,733,753)			$ 9,224,614
Balance (in shares) at Dec. 31, 2021			7					12,663,965